Vimta Labs Ltd

- There is no mention of any current or immediate plans for fundraising through debt or equity in the provided transcript. - The company discusses ongoing capex funded mainly through internal accruals, specifically from depreciation of previous years. - The management indicates a focus on organic growth with investments in capacity expansion and new service lines like biologics. - While inorganic growth through acquisitions is mentioned as a possibility in principle, there are no active plans or deals currently on the table. - No direct references to raising debt or issuing equity for funding purposes were made during the call.

- Vimta Labs is continuing to invest in capacity expansion, especially to support growth in defense-related EMI/EMC testing, adding a qualified new chamber recently. - To sustain growth, the company plans to open more laboratories in the future. - Recent capex has included significant infrastructure expansion and new biologics, formulation, and process development services. - Equipment procurement and facility setup for biologics contract research and development services are on track, with commercialization expected by Q1 FY '27. - Capex typically aligns with depreciation from the previous year to avoid technological obsolescence and support revenue growth. - There is a principle-level openness to inorganic growth, but currently, no immediate acquisitions or investments are planned. - Facility expenses have increased due to these expansions, including a new large facility recently added.

- Vimta Labs is confident about good near-term and long-term growth due to favorable markets in pharma, food testing, preclinical and clinical research, and electronics testing. - The company does not provide specific forward-looking revenue numbers but remains optimistic about growth. - The target of INR 500 crores revenue for the next fiscal year remains aligned. - Q4 is expected to witness higher revenues, supporting growth trajectory. - Capacity expansions, including doubling electronics and electrical testing capacity, aim to support sales growth. - New service lines like biologics contract research and development services are expected to commercialize from Q1 FY ‘27, contributing to future revenue. - Increasing marketing efforts overseas and adding laboratory facilities will further enable growth. - Seasonal businesses like food testing are expected to improve in Q4. - Continuous digital transformation and operational efficiency improvements are expected to support margin and volume growth.

- Vimta Labs expresses confidence in continued growth driven by favorable market conditions across pharma, food testing, and electronics sectors. - The company targets INR 500 crores revenue for the next fiscal year but refrains from providing firm forward-looking guidance. - EBITDA margins expected to maintain near current levels (±1-2%) with ongoing digital transformation and AI integration supporting efficiency gains. - Operational challenges caused minor revenue deferrals in Q3, with Q4 projected to show improved performance. - New biologics contract research and development services to commercialize from Q1 FY '27; revenues expected to start small initially. - Firm focus on expanding laboratory capacities and new testing chambers to support growth. - ROCE expected to normalize back above 20% following current investment phase. - Export revenues growing, with approx. 39% of income from exports and 60% of that from the U.S., supporting growth. - Employee and other expenses increasing moderately due to overseas marketing and new facility costs but controlled.

- The company has initiated new projects, with one already underway and another in the initiation phase, but their current revenue impact is minimal as the projects are recent. - Clinical trial bookings experienced some lag in the quarter, leading to deferred revenues. - Biologics contract research and development services are gearing up, with commercialization expected by Q1 FY '27, though no significant revenues are anticipated immediately. - Market conditions across pharma, food testing, and electronics testing remain favorable, supporting order book growth. - Facility expansions and new capacity additions, especially in electronics/EMC testing and biologics, indicate preparation for increasing order volumes. - No explicit numerical order book figures were disclosed; however, management expressed confidence in growth and continuous inflow of new orders.